SITE003-0130

SITE003 (CAN) › SITE003-0130

SITE003-0130

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-02-05

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 164); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-28 (study day 78); relationship: not assessed

moderate assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 37); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.